MedTrace Logo

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

NCT04821206 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2021-03-29

No results posted yet for this study

Summary

This prospective, non-interventional, research registry is designed to study the comparative safety and comparative effectiveness of approved Jak Inhibitors treatment for RA-PsA-SpA in a cohort of patients and theirs controls cared for by rheumatologists across Latin América (LA).

Conditions

  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Spondyloarthritis

Interventions

DRUG

DMARDs

New Initiation of a DMARDs

DRUG

biologic DMARDs

New Initiation of a biologic DMARDs

DRUG

JAK Inhibitor

New Initiation of a JAK Inhibitor

Sponsors & Collaborators

  • Liga Panamericana de Asociaciones de Reumatologia (PANLAR)

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-02-01
Completion
2024-07-01
FDA Drug
Yes

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04821206 on ClinicalTrials.gov